PMID- 11830514
OWN - NLM
STAT- MEDLINE
DCOM- 20020305
LR  - 20220224
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 62
IP  - 3
DP  - 2002 Feb 1
TI  - Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, 
      proliferation, and transformed phenotype of breast cancer cells.
PG  - 652-5
AB  - Overexpression of the epidermal growth factor receptor family member Her-2/neu in 
      breast cancer is associated with poor prognosis. With evidence accumulating for a 
      chemopreventive role of green tea polyphenols, the effects of epigallocatechin-3 
      gallate (EGCG) on Her-2/neu-overexpressing breast cancer cells were examined. 
      EGCG inhibited mouse mammary tumor virus (MMTV)-Her-2/neu NF639 cell growth in 
      culture and soft agar. EGCG reduced signaling via the phosphatidylinositol 3- 
      kinase, Akt kinase to NF-kappaB pathway because of inhibition of basal Her-2/neu 
      receptor tyrosine phosphorylation. EGCG similarly inhibited basal receptor 
      phosphorylation in SMF and Ba/F3 2 + 4 cells, which suggests the potential 
      beneficial use of EGCG in adjuvant therapy of tumors with Her-2/neu 
      overexpression.
FAU - Pianetti, Stefania
AU  - Pianetti S
AD  - Department of Biochemistry, Boston University School of Medicine, 715 Albany 
      Street, Boston, MA 02118-2394, USA.
FAU - Guo, Shangqin
AU  - Guo S
FAU - Kavanagh, Kathryn T
AU  - Kavanagh KT
FAU - Sonenshein, Gail E
AU  - Sonenshein GE
LA  - eng
GR  - P01 ES 11624/ES/NIEHS NIH HHS/United States
GR  - R01 CA 82742/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Growth Inhibitors)
RN  - 0 (NF-kappa B)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 8R1V1STN48 (Catechin)
RN  - BQM438CTEL (epigallocatechin gallate)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Animals
MH  - Anticarcinogenic Agents/*pharmacology
MH  - Beverages
MH  - Catechin/analogs & derivatives/*pharmacology
MH  - Cell Division/drug effects
MH  - Cell Transformation, Neoplastic/*drug effects
MH  - Female
MH  - Growth Inhibitors/pharmacology
MH  - Mammary Neoplasms, Experimental/*pathology/prevention & control
MH  - Mice
MH  - NF-kappa B/antagonists & inhibitors/physiology
MH  - Phosphatidylinositol 3-Kinases/physiology
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - Phosphorylation/drug effects
MH  - *Protein Serine-Threonine Kinases
MH  - Proto-Oncogene Proteins/antagonists & inhibitors/physiology
MH  - Proto-Oncogene Proteins c-akt
MH  - Receptor, ErbB-2/*antagonists & inhibitors/physiology
MH  - Signal Transduction/drug effects
EDAT- 2002/02/07 10:00
MHDA- 2002/03/07 10:01
CRDT- 2002/02/07 10:00
PHST- 2002/02/07 10:00 [pubmed]
PHST- 2002/03/07 10:01 [medline]
PHST- 2002/02/07 10:00 [entrez]
PST - ppublish
SO  - Cancer Res. 2002 Feb 1;62(3):652-5.